Vor Biopharma (NASDAQ:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 11,616 Shares of Stock

Vor Biopharma Inc. (NASDAQ:VOR) major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $30.05, for a total value of $349,060.80. Following the completion of the sale, the insider owned 1,167,109 shares of the company’s stock, valued at approximately $35,071,625.45. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, October 21st, Reprogrammed Interchange Llc sold 200 shares of Vor Biopharma stock. The shares were sold at an average price of $30.07, for a total transaction of $6,014.00.
• On Friday, October 17th, Reprogrammed Interchange Llc sold 25,717 shares of Vor Biopharma stock. The stock was sold at an average price of $30.25, for a total transaction of $777,939.25.
• On Thursday, October 16th, Reprogrammed Interchange Llc sold 2,021 shares of Vor Biopharma stock. The stock was sold at an average price of $30.45, for a total transaction of $61,539.45.
• On Wednesday, October 15th, Reprogrammed Interchange Llc sold 71,655 shares of Vor Biopharma stock. The shares were sold at an average price of $31.92, for a total transaction of $2,287,227.60.
• On Tuesday, October 14th, Reprogrammed Interchange Llc sold 33,668 shares of Vor Biopharma stock. The stock was sold at an average price of $30.32, for a total transaction of $1,020,813.76.
• On Monday, October 13th, Reprogrammed Interchange Llc sold 22,006 shares of Vor Biopharma stock. The stock was sold at an average price of $32.44, for a total transaction of $713,874.64.
• On Friday, October 10th, Reprogrammed Interchange Llc sold 40,983 shares of Vor Biopharma stock. The shares were sold at an average price of $30.97, for a total transaction of $1,269,243.51.
• On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The shares were sold at an average price of $32.07, for a total value of $1,567,709.88.
• On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The stock was sold at an average price of $33.87, for a total value of $2,549,123.94.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The shares were sold at an average price of $33.84, for a total value of $934,796.16.

Vor Biopharma Trading Down 5.6%

Shares of NASDAQ VOR opened at $27.77 on Wednesday. Vor Biopharma Inc. has a 12 month low of $2.62 and a 12 month high of $65.80. The company has a market cap of $190.34 million, a P/E ratio of -0.10 and a beta of 2.07. The stock has a 50 day simple moving average of $36.24.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ariose Capital Management Ltd bought a new stake in shares of Vor Biopharma in the 3rd quarter valued at approximately $5,368,000. XTX Topco Ltd bought a new position in shares of Vor Biopharma during the 2nd quarter worth approximately $66,000. Goldman Sachs Group Inc. boosted its stake in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares in the last quarter. Jane Street Group LLC bought a new stake in Vor Biopharma in the first quarter valued at $140,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Vor Biopharma during the first quarter worth $100,000. Institutional investors own 97.29% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Robert W. Baird upgraded shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $20.00 to $64.00 in a report on Wednesday, October 15th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Vor Biopharma in a research note on Thursday, August 14th. Wedbush reaffirmed an “outperform” rating on shares of Vor Biopharma in a report on Thursday, June 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Finally, Zacks Research cut Vor Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $77.83.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.